spacer
The Healthcare Sales & Marketing Network celebrates 21 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  aliskiren 

 HSMN NewsFeed - 15 Nov 2017
Noden Pharma Announces FDA Approval of Tekturna(R) (aliskiren) Oral Pellets for the Treatment of Hypertension in Adults and Children 6 Years of Age and Older
Biopharmaceuticals Cardiology FDA
 HSMN NewsFeed - 6 Jun 2016
Allergan Announces FDA Approval of BYVALSON(TM) (nebivolol and valsartan)
Biopharmaceuticals Cardiology FDA
 HSMN NewsFeed - 19 May 2014
Genkyotex Announces New Senior Management and Board Appointments
Biopharmaceuticals Personnel
 HSMN NewsFeed - 27 Aug 2010
Novartis receives FDA approval of Tekamlo, a single-pill combination of aliskiren and amlodipine to treat high blood pressure
Biopharmaceuticals Cardiology FDA
 HSMN NewsFeed - 21 Jul 2009
FDA Approves Tekturna HCT(R) as Initial Treatment in Patients Unlikely to Achieve Their Blood Pressure Goals With a Single Agent
Biopharmaceuticals FDA
 HSMN NewsFeed - 1 Apr 2008
SPP100 (Tekturna/Rasilez) Reduces Left Ventricular Hypertrophy
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 21 Jan 2008
US Approval for SPP100 Combined with Diuretic to Treat Hypertension
Biopharmaceuticals FDA
 HSMN NewsFeed - 27 Aug 2007
SPP100 (Rasilez) Receives EU Approval
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 21 May 2007
Single-Tablet Combination of Tekturna(R) and Diuretic, an Important New Option for People With High Blood Pressure, Accepted for Review in U.S.
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 26 Mar 2007
Tekturna(R), First New Type of High Blood Pressure Medicine in a Decade, Provides Additional Blood Pressure Reduction When Used With Diovan(R)
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 6 Mar 2007
Tekturna(R) - The First New Type of High Blood Pressure Medicine In More Than a Decade - Receives Its First Approval in the US
Biopharmaceuticals Cardiology FDA
 HSMN NewsFeed - 17 May 2006
New Phase III Data on Renin Inhibitor SPP100 (Rasilez) in Treatment of Hypertension Demonstrates Potential of This First-in-Class Drug
Biopharmaceuticals
 HSMN NewsFeed - 17 May 2006
Novartis Announces Efficacy Data on New Investigational High Blood Pressure Therapies at The American Society of Hypertension Annual Meeting
Biopharmaceuticals
 HSMN NewsFeed - 1 May 2006
FDA Approves Higher Dose Formulations of Diovan HCT(R) (valsartan/hydrochlorothiazide) for Treatment of High Blood Pressure
Biopharmaceuticals FDA
 HSMN NewsFeed - 20 Apr 2006
New Drug Application (NDA) for Rasilez(R) (Aliskiren), an Innovative Oral Renin Inhibitor to Treat High Blood Pressure, Accepted for Review by the US FDA
Biopharmaceuticals
 HSMN NewsFeed - 20 Apr 2006
Filing for U.S. Approval of Renin Inhibitor SPP100 (Rasilez) in Treatment of Hypertension by Novartis
Biopharmaceuticals
 HSMN NewsFeed - 19 Jan 2006
Novartis New Phase III Data With SPP100 (aliskiren, Rasilez) Reconfirms Strong Efficacy and Excellent Safety Profile as Monotherapy and Co-Administration Therapy for Treatment of Hypertension
Biopharmaceuticals
Return to NewsFeed  

 Additional items found! 5

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 5 additional stories matching:
aliskiren
(Password required)
FindReps 2 - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps 2 - available on the Apple App Store for iPhone and iPad.